Effect of Metabolites of Lactobacillus Strains on Clinical Isolates of the Human Intestinal Microbiota
DOI:
https://doi.org/10.15407/microbiolj87.02.003Keywords:
metabolites, pharmabiotics, intestinal microbiota, 3P medicineAbstract
Currently, most clinically effective pharmabiotics are based on bacterial strains of the genus Lactobacillus. The antimicrobial properties of these microorganisms are attributed to their unique ability to synthesize metabolites that have significant potential in combating pathogenic microorganisms. The aim of this work was to study the effect of the metabolites of six probiotic Lactobacillus strains in vitro on opportunistic and commensal representatives of the human gut microbiota. Methods. Metabolites were isolated from six proprietary probiotic Lactobacillus strains (Lactobacillus plantarum A, L. bulgaricus A6, L. bulgaricus A22, L. bulgaricus S6, L. bulgaricus S19, and L. rhamnosus S25) by filtering the supernatant using syringe cellulose acetate membrane nanofilters with a pore diameter of 0.22 μm. The effect of the metabolites was evaluated against opportunistic (Escherichia coli, Enterobacter cloacae, Proteus mirabilis, Bacillus cereus, and Staphylococcus aureus) and commensal (Enterococcus faecalis, L. plantarum) intestinal microbiota strains. Cultures were performed on agarized selective and differential diagnostic nutrient media. Microsoft Office Excel software was used for statistical processing of the experimental results. Results. Our study has shown that the metabolites of L. plantarum A, L. bulgaricus A6, L. bulgaricus S19, and L. rhamnosus S25 strains are characterized by the maximum ability to suppress the growth of E. coli, lac - on Day 1 of co-cultivation. Already on Day 2, the metabolites of L. plantarum A strain completely inhibited the growth of E. coli, lac -. The metabolites of probiotic L. bulgaricus A22 and L. bulgaricus S19 strains inhibited the growth of E. coli, lac - on Day 2 slightly less effectively. On Day 1 of co-cultivation, the metabolites of L. bulgaricus A6, L. bulgaricus A22, L. bulgaricus S6, and L. rhamnosus S25 strains showed the highest inhibitory effect on E. cloacae. However, on Day 2, the metabolites of L. plantarum A strain were the most effective, completely inhibiting the growth of E. cloacae. According to the study results, the metabolites of L. bulgaricus A6, L. bulgaricus A22, and L. bulgaricus S19 strains showed the best antagonistic effect on P. mirabilis. On Day 2 of co-cultivation, the metabolites of L. plantarum A strain completely inhibited the growth of P. mirabilis. The metabolites of L. bulgaricus A22, L. bulgaricus S6, L. bulgaricus S19, and L. rhamnosus S25 strains also showed an antagonistic effect on P. mirabilis on Day 2, but to a lesser degree. After 24 h, the metabolites of L. bulgaricus S19 and L. rhamnosus S25 strains turned out to be the most effective toward B. cereus. However, after 48 h of co-cultivation, it was the metabolites of L. plantarum A strain that demonstrated the best inhibitory properties, while the metabolites of L. bulgaricus S6 and L. bulgaricus S19 strains showed less efficacy. When studying the properties of the metabolites of probiotic Lactobacillus strains in relation to commensal representatives of the human gastrointestinal tract (E. faecalis and L. plantarum), in most cases, we noted no inhibition of commensal bacteria growth. In some cases, the addition of metabolites into the nutrient medium during the cultivation of E. faecalis and L. plantarum was noted to stimulate the growth of the latter. On Day 1 of co-cultivation, the metabolites of L. plantarum A, L. bulgaricus A6, L. bulgaricus S19, and L. rhamnosus S25 strains did not inhibit the growth of E. faecalis. However, on Day 2, it was found that the metabolites of L. plantarum A and L. bulgaricus A6 strains showed a stimulating effect on this test strain. On Day 1 of cultivation, the metabolites of strain L. bulgaricus S19 showed a stimulating effect on L. plantarum. On Day 2, the metabolites of strain L. bulgaricus S6 were the most effective, also demonstrating a stimulating effect. Conclusions. We anticipate the potential application of metabolites from the probiotic Lactobacillus strains for personalized modification of the human microbiome, which is particularly important in the context of advanced approaches to the modern 3P medicine.
Downloads
References
Aguilar-Toalá, J. E., Garcia-Varela, R., Garcia, H. S., Mata-Haro, V., González-Córdova, A. F., Vallejo-Cordoba, B., & Hernández-Mendoza, A. (2018). Postbiotics: An evolving term within the functional foods field. Trends in food science & technology, 75, 105-114. https://doi.org/10.1016/j.tifs.2018.03.009
Boyko, N., & Golubnitschaja, O. (Eds.). (2023). Microbiome in 3P Medicine Strategies: The First Exploitation Guide (Vol. 16). Springer Nature. https://doi.org/10.1007/978-3-031-19564-8
Capuco, A., Urits, I., Hasoon, J., Chun, R., Gerald, B., Wang, J. K., et al. (2020). Current perspectives on gut microbiome dysbiosis and depression. Advances in therapy, 37, 1328-1346. https://doi.org/10.1007/s12325-020-01272-7
Golubnitschaja, O., Baban, B., Boniolo, G., Wang, W., Bubnov, R., Kapalla, M., et al. (2016). Medicine in the early twenty-first century: paradigm and anticipation-EPMA position paper 2016. EPMA Journal, 7(1), 23. https://doi.org/10.1186/s13167-016-0072-4
Hasan, F. B., Reza, M., Al Masud, H. A., Uddin, M. K., & Uddin, M. S. (2019). Preliminary characterization and inhibitory activity of bacteriocin like substances from Lactobacillus casei against multi-drug resistant bacteria. Bangladesh J Microbiol, 36(1), 1-6. https://doi.org/10.3329/bjm.v36i1.44259
Liu, B. N., Liu, X. T., Liang, Z. H., & Wang, J. H. (2021). Gut microbiota in obesity. World Journal of Gastroenterology, 27(25), 3837. https://doi.org/10.3748/wjg.v27.i25.3837
Meleshko, T., Rukavchuk, R., Drobnych, V., & Boyko, N. (2020). Personalized pharmabiotics and individual nutrition for nosology specific correction of microbiota and local immune system biomarkers. 10th Anniversary of the European Association for Predictive, Preventive and Personalised (3P) Medicine - EPMA World Congress Supplement 2020. – Pilsen, Czech Republic, 2020. – Р. 125-127.
Nataraj, B. H., Ali, S. A., Behare, P. V., & Yadav, H. (2020). Postbiotics-parabiotics: The new horizons in microbial biotherapy and functional foods. Microbial cell factories, 19(1), 1-22. https://doi.org/10.1186/s12934-020-01426-w
Pimentel, M., & Lembo, A. (2020). Microbiome and its role in irritable bowel syndrome. Digestive diseases and sciences, 65, 829-839. https://doi.org/10.1007/s10620-020-06109-5
Scillato, M., Spitale, A., Mongelli, G., Privitera, G. F., Mangano, K., Cianci, A., et al. (2021). Antimicrobial properties of Lactobacillus cell‐free supernatants against multidrug‐resistant urogenital pathogens. Microbiologyopen, 10(2), e1173. https://doi.org/10.1002/mbo3.1173
Shreiner, A. B., Kao, J. Y., & Young, V. B. (2015). The gut microbiome in health and in disease. Current opinion in gastroenterology, 31(1), 69. https://doi.org/10.1097/MOG.0000000000000139
Sikalidis, A. K., & Maykish, A. (2020). The gut microbiome and type 2 diabetes mellitus: discussing a complex relationship. Biomedicines, 8(1), 8. https://doi.org/10.3390/biomedicines8010008
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Mikrobiolohichnyi Zhurnal
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
